RecruitingNot Applicable

A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer

China60 participantsStarted 2025-11-10

Plain-language summary

Evaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patients with high-grade serous adenocarcinoma (HGSOC) with FIGO stage IIIC-IVA.
✓. Age between 18 and 70.
✓. Patients were evaluated with Fagotti score and MD Anderson score. MD Anderson score was consistent with Fagotti score ≥ 8, which was evaluated as high tumor load, because the initial curative resection could not achieve R0 resection and NACT was selected; or patients could not tolerate the initial surgery due to severe complications and NACT was selected.
✓. Normal renal function (blood creatinine: 58-96 μmol/L).
✓. No bone marrow suppression (HBG ≥ 110 g/L, white blood cell count ≥ 4.0×109/L, neutropenia Granulocyte count greater than or equal to 2.0x109/L and platelet count greater than or equal to 100x109/L).
✓. Normal liver function (bilirubin 3.4-22.2 μmol/L, ALT 7-40 U/L, AST 13-35 U/L, AST/ALT≤ 1.5）。
✓. World Health Organization Performance status score (WHO score) 0-2 points.

Can PIPAC increase the incidence of CRS3

Timeframe: Two years

NCT IDNCT07544030

Sponsortongweihua

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-11-10

Xiaosen Li Li